Medifocus Guidebook on Chronic Lymphocytic Leukemia
Medifocus Guidebook on Chronic Lymphocytic Leukemia
HomeWho We AreMedical Advisory BoardContactSupport Share|
Medifocus Guidebook on Chronic Lymphocytic Leukemia
Updated: August 24, 2010
135 Pages
What is Chronic Lymphocytic Leukemia?
Leukemia is a cancer of the white blood cells that arises from the bone marrow and circulates in the peripheral blood. It is characterized by uncontrolled growth of white blood cells. Leukemia is a disease of the blood cells and does not usually form a solid mass or tumor. Although leukemia starts in the bone marrow, it can spread to the blood, lymph nodes, spleen, liver, central nervous system (CNS) and other organs.
There are four major types of leukemias:
•Acute myelogenous leukemia (AML)
•Chronic myelogenous leukemia (CML)
•Acute lymphocytic leukemia (ALL)
•Chronic lymphocytic leukemia (CLL)
The terms "myelogenous" and "lymphocytic" denote the different types of cell involved. The terms "acute" or "chronic" refer to the rate of progression of the disease.
Acute leukemia is a rapidly progressing disease that results in the accumulation of immature, non-functional cells in the marrow and blood. As a result, the bone marrow often can no longer produce enough normal red blood cells, white blood cells, and platelets. Chronic leukemia progresses more slowly and permits greater numbers of more mature functional cells to be made.
According to the American Cancer Society, approximately 15,490 new cases of chronic lymphocytic leukemia (CLL) were diagnosed in 2009 in the United States. Chronic lymphocytic leukemia affects males more than females with men accounting for about 60% of all CLL cases. The incidence of CLL is much higher in Western countries than in Asian countries such as China and Japan.
Chronic lymphocytic leukemia represents approximately 25% of all leukemias and occurs most frequently in the elderly population. The median age at the time of diagnosis is 70. Chronic lymphocytic leukemia usually does not develop in people under age 40 and is also extremely rare in children The incidence of CLL in the United States is higher in Caucasians than in African Americans. Recent research indicates that the 5-year survival rate of patients with CLL is 73%. The American Cancer Society estimates that about 4,500 people in the U.S. will die of CLL in 2007.
Knowledge is Critical when Dealing with a Life-Altering Condition such as Chronic Lymphocytic Leukemia
If you or a loved one has been diagnosed with CLL, it's critical to learn everything you possibly can about this condition so that you can make informed decisions about your treatment. That's why we created the Medifocus Guidebook on Chronic Lymphocytic Leukemia, a comprehensive 135 page patient Guidebook that contains vital information about CLL that you won't find anywhere in a single source.
The Medifocus Guidebook on Chronic Lymphocytic Leukemia starts out with a detailed overview of the condition and quickly imparts fundamentally important information about CLL, including:
•The theories concerning the underlying causes of CLL.
•The specific types of genetic mutations that are found in people with CLL.
•The risk factors that can increase a person's chances for developing CLL.
•How CLL is diagnosed based on factors such as signs/symptoms, physical examination, blood tests, and specific genetic abnormalities.
•A detailed description of the two major staging systems, called Rai and Binet, that doctors use in order to:
◦Determine the extent of progression of the disease
◦Develop an optimal treatment plan
◦Predict the most likely outcome (prognosis) in terms of expected years of survival
Understanding the Standard Treatments...and the Treatment Options
Because currently there is no known cure for CLL, understanding the standard treatments - and the treatment options - is critical in attempting to prolong survival and maintain the patient's overall functional ability and quality of life. As you read through the section of the Guidebook that focuses on the treatments for CLL, you will specifically learn about:
•Which patients with CLL do not require any treatment for several years and may benefit from a "watchful waiting" approach where the disease progression is monitored carefully but no specific CLL treatment is given.
•The National Cancer Institutes guidelines for determining when initial treatment of CLL is indicated and should be started.
•The two most commonly used classes of chemotherapeutic agents that are used for the treatment of CLL, known as alkylating agents and purine nucleoside analogs.
•A new alkylating agent called bendamustine (Treanda) that was recently approved for the treatment of CLL.
•The side-effects associated with CLL chemotherapy and how to minimize their impact on your quality of life.
•A novel approach known as monoclonal antibody immunotherapy that has recently come into clinical practice which gives doctors the ability to preferentially target and destroy CLL cells. Examples of monoclonal antibodies that may be used for the treatment of CLL include:
◦Alemtuzumab (Campath)
◦Rituximab (Rituxan)
◦Ofatumumab (Arzerra) - a new monoclonal antibody that was approved for the treatment of CLL in October 2009.
•The role of stem cell transplantation in the management of patients with CLL, including the risks and benefits of this procedure.
•The complications, such as infection, anemia, and secondary cancers that may occur in people with CLL, including the management of these serious complications.
•The treatment options for patients with CLL who experience recurrent disease, meaning that the leukemia has come back after the patient had been in remission for a period of time.
•The role of complementary and alternative therapies in the management of patients with CLL.
•The prognosis (outlook) for people with CLL and the important factors that have a significant impact in predicting the overall chances of recovery and survival.
•Quality of life issues such as sleep disorders, fatigue, weight loss, and psychological stress that can negatively affect people with CLL and how to minimize the impact and cope better with these issues.
•Important questions to ask your doctor about CLL.
A "One-of-a-Kind" Reference Guidebook on Chronic Lymphocytic Leukemia that Goes Way Beyond the Fundamentals
Since 1996, when Medifocus was founded, we've learned that many people with Chronic Lymphocytic Leukemia are seeking more specific information that goes beyond the fundamentals, such as the causes, diagnosis, standard treatments, and treatment options. That's why we developed a "one-of-a-kind" reference Guidebook that goes way beyond the basics and also includes the following sections:
•A Guide to Recent Medical Literature on Chronic Lymphocytic Leukemia - This section of the Guidebook contains an extensive bibliography of over 100 references to recently published articles about Chronic Lymphocytic Leukemia in authoritative, peer-reviewed medical journals with links to the absracts (summaries) of the articles. These articles represent the latest advances in the field and focus on cutting-edge research, new developments, and the lessons learned from recently published clinical trials involving patients with Chronic Lymphocytic Leukemia. This is the same level of that is used by doctors who treat people with Chronic Lymphocytic Leukemia to keep abreast of the latest developments and breakthroughs in this specialized field of medicine.
•Centers of Research for Chronic Lymphocytic Leukemia - We've compiled a unique directory of doctors, hospitals, medical centers, and research institutions with special interest and, in many cases, clinical expertise in managing people with Chronic Lymphocytic Leukemia. The "Centers of Research" directory is a valuable resource for quickly identifying and locating leading medical authorities and medical institutions both within the United States and other countries who are considered to be at the forefront in clinical research and treatment of Chronic Lymphocytic Leukemia. You'd have to spend days - or even weeks - attempting to compile your own list of doctors and medical centers but, with the "Centers of Research" directory, the information is already right at your fingertips. All you have to do is act on the information by selecting and contacting the experts or medical institutions listed in the directory by state and country.
•Organizations and Support Groups for Chronic Lymphocytic Leukemia - The Guidebook also includes a directory of organizations and support groups whose goal is to help people with Chronic Lymphocytic Leukemia by providing access to information, resources, and services. Many of these organizations can answer your specific questions, enable you to "network" with other patients, and provide guidance in areas such as financial, social, or medical-legal issues. This valuable directory of organizations and support groups includes complete contact information, including phone numbers and E-mail addresses.
The Guidebook is a Value-Added Proposition that Comes with a Risk-Free Satisfaction Guarantee so that...You have Nothing to Lose and Everything to Gain
Still not sure if you'll benefit from the Medifocus Guidebook on Chronic Lymphocytic Leukemia? Still not convinced that the information included in the Guidebook is worth the minimal cost? If that's the case, then please consider the following value-added proposition that comes standard with your purchase of the Guidebook:
•Free Updates for One Year - With your initial purchase of the Guidebook, you also receive access to free updates for one-full year. The Guidebook is updated with new information every 4 to 6 months, so that you will be able to access the updated information several times during the course of a year for up to one full year after the date of your initial purchase.
•Free Digest E-Mail Alerts - When you purchase the Guidebook, you will also automatically receive a free subscription to our monthly newsletter - the Medifocus Digest Alert for Chronic Lymphocytic Leukemia. This is an expertly selected listing of the latest articles published in the medical literature about Chronic Lymphocytic Leukemia with convenient links to the abstracts of the articles that focus on cutting-edge research, clinical trials, and the latest treatment advances. The Medifocus Digest Alert for Chronic Lymphocytic Leukemia is automatically delivered straight to your "inbox" monthly and is a valuable resource for keeping up with the latest developments in Chronic Lymphocytic Leukemia almost as soon as the new information is published in the medical literature.
•10% Discount - For a limited time, you can purchase the Medifocus Guidebook on Chronic Lymphocytic Leukemia at a special 10% discount off the regular list price. Your 10% discount will automatically be applied when you go to "Checkout".
•Risk-Free Satisfaction Guarantee - Your purchase comes with our RISK-FREE satisfaction guarantee. If, for whatever reason, you are not totally satisfied with the content of your Guidebook, simply contact us within 30-days of your purchase for a prompt, full refund. We are so confident that you will be satisfied with your Guidebook that we offer this RISK-FREE satisfaction guarantee unconditionally - no questions and no hassles.
Order Your Copy of the Medifocus Guidebook on Chronic Lymphocytic Leukemia Today!
The Medifocus Guidebook on Chronic Lymphocytic Leukemia (135 pages; last updated August 24, 2010) is available in the following two convenient formats:
•PRINTED GUIDEBOOK - Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.):
◦Regular List Price = $32.95
◦Less 10% Discount = - $3.30
◦Your Discounted Price = $29.65 (excluding shipping & handling)
•ELECTRONIC GUIDEBOOK - Available for immediate download as a PDF document:
◦Regular List Price = $24.95
◦Less 10% Discount = - $2.50
◦Your Discounted Price = $22.45
To Place Your Order by Telephone, please call us:
•Within the United States (toll free): 1-800-965-3002
•Outside the United States: 1-301-649-9300
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia
at a Special 10% Discount
Updated: August 24, 2010
135 Pages
This one of a kind Guidebook offers:
•Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
•High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
•Timely, up to date content with free guidebook updates for 1 year.
•A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
•Over 130,000 Guidebooks Sold
•100% Risk Free Money Back Guarantee
--------------------------------------------------------------------------------
Purchase this Guidebook
The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:
PRINTED GUIDEBOOK - Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.):
•Regular List Price = $32.95
•Less 10% Discount = - $3.30
•Discounted Price = $29.65 (excluding shipping & handling)
ELECTRONIC GUIDEBOOK - Available for immediate download as a PDF document:
•Regular List Price = $24.95
•Less 10% Discount = - $2.50
•Discounted Price = $22.45
Order by Telephone
Call Toll Free in the U.S.
800-965-3002
From Outside the U.S.
301-649-9300
--------------------------------------------------------------------------------
What Our Customers Are Saying...
"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom
--------------------------------------------------------------------------------
Get the Medifocus Digest Alert on Chronic Lymphocytic Leukemia. Yours FREE! View Sample
Enter your email address:
I have read and agreed to the Medifocus Privacy Policy.
HomeWho We AreMedical Advisory BoardContactSupport
Privacy Policy © 1996-2010 Medifocus.com, Inc. or its affiliates Page Updated on: August 24, 2010
Medifocus Digest Alert
Each month hundreds of thousands of consumers and healthcare professionals search the National Library of Medicine's MEDLINE database seeking the latest information on their disease/condition. Conducting a thorough and effective MEDLINE search is both a time consuming and daunting task. At Medifocus, we have developed an effective solution to this problem that we call the Medifocus Digest Alert. Each month our staff of expert researchers searches MEDLINE for the latest advances in research and clinical medicine for over 30 diseases/conditions.
The Medifocus Digest Alert is an expertly selected listing of the latest medical journal articles published in MEDLINE for each disease/condition with direct links to the specific article summaries (abstracts) focusing on CUTTING EDGE RESEARCH, CLINICAL TRIALS, and the LATEST TREATMENT ADVANCES.
When you subscribe to the Medifocus Digest Alert, it is likely that you will have access to newly published information about your disease/condition even sooner than your doctor! And best of all...subscribing to the Medifocus Digest Alert is absolutely FREE.
STEP 1: SELECT YOUR DISEASES/CONDITIONS OF INTEREST STEP 2: ENTER YOUR EMAIL ADDRESS
Abdominal Aortic Aneurysm
Acoustic Neuroma
Alzheimer's Disease
Ankylosing Spondylitis
Atrial Fibrillation
Bipolar Disorder
Bladder Cancer
Carcinoid Tumor
Chronic Fatigue Syndrome
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Chronic Obstructive Pulmonary Disease
Chronic Pancreatitis
Cluster Headache
Congestive Heart Failure
Ductal Carcinoma in Situ of the Breast
Erectile Dysfunction
Female Infertility
Fibromyalgia
Gastroesophageal Reflux Disease
Glioblastoma
Graves' Disease
Hereditary Hemochromatosis
Lymphedema
Meniere's Disease
Migraine Headache
Multiple Myeloma
Myelodysplastic Syndromes
Non-Hodgkin's Lymphoma
Non-Small Cell Lung Cancer
Obsessive-Compulsive Disorder
Obstructive Sleep Apnea Syndrome
Osteoarthritis of the Knee
Osteoporosis
Parkinson's Disease
Peripheral Neuropathy
Polycystic Kidney Disease
Polycystic Ovary Syndrome
Reflex Sympathetic Dystrophy
Renal Cell Carcinoma
Restless Legs Syndrome
Rheumatoid Arthritis
Scleroderma
Sjogren's Syndrome
Small Cell Lung Cancer
Spondylolisthesis
Stroke Rehabilitation
Thoracic Outlet Syndrome
Tongue Cancer
Trigeminal Neuralgia
Vertigo
Email:
I have read and agreed to the Medifocus Privacy Policy.
HomeWho We AreMedical Advisory BoardContactSupportPrivacy Policy © 1996-2010 Medifocus.com, Inc. or its affiliates
HomeWho We AreMedical Advisory BoardContactSupport Share|
Medifocus Guidebook on Chronic Lymphocytic Leukemia
Updated: August 24, 2010
135 Pages
What is Chronic Lymphocytic Leukemia?
Leukemia is a cancer of the white blood cells that arises from the bone marrow and circulates in the peripheral blood. It is characterized by uncontrolled growth of white blood cells. Leukemia is a disease of the blood cells and does not usually form a solid mass or tumor. Although leukemia starts in the bone marrow, it can spread to the blood, lymph nodes, spleen, liver, central nervous system (CNS) and other organs.
There are four major types of leukemias:
•Acute myelogenous leukemia (AML)
•Chronic myelogenous leukemia (CML)
•Acute lymphocytic leukemia (ALL)
•Chronic lymphocytic leukemia (CLL)
The terms "myelogenous" and "lymphocytic" denote the different types of cell involved. The terms "acute" or "chronic" refer to the rate of progression of the disease.
Acute leukemia is a rapidly progressing disease that results in the accumulation of immature, non-functional cells in the marrow and blood. As a result, the bone marrow often can no longer produce enough normal red blood cells, white blood cells, and platelets. Chronic leukemia progresses more slowly and permits greater numbers of more mature functional cells to be made.
According to the American Cancer Society, approximately 15,490 new cases of chronic lymphocytic leukemia (CLL) were diagnosed in 2009 in the United States. Chronic lymphocytic leukemia affects males more than females with men accounting for about 60% of all CLL cases. The incidence of CLL is much higher in Western countries than in Asian countries such as China and Japan.
Chronic lymphocytic leukemia represents approximately 25% of all leukemias and occurs most frequently in the elderly population. The median age at the time of diagnosis is 70. Chronic lymphocytic leukemia usually does not develop in people under age 40 and is also extremely rare in children The incidence of CLL in the United States is higher in Caucasians than in African Americans. Recent research indicates that the 5-year survival rate of patients with CLL is 73%. The American Cancer Society estimates that about 4,500 people in the U.S. will die of CLL in 2007.
Knowledge is Critical when Dealing with a Life-Altering Condition such as Chronic Lymphocytic Leukemia
If you or a loved one has been diagnosed with CLL, it's critical to learn everything you possibly can about this condition so that you can make informed decisions about your treatment. That's why we created the Medifocus Guidebook on Chronic Lymphocytic Leukemia, a comprehensive 135 page patient Guidebook that contains vital information about CLL that you won't find anywhere in a single source.
The Medifocus Guidebook on Chronic Lymphocytic Leukemia starts out with a detailed overview of the condition and quickly imparts fundamentally important information about CLL, including:
•The theories concerning the underlying causes of CLL.
•The specific types of genetic mutations that are found in people with CLL.
•The risk factors that can increase a person's chances for developing CLL.
•How CLL is diagnosed based on factors such as signs/symptoms, physical examination, blood tests, and specific genetic abnormalities.
•A detailed description of the two major staging systems, called Rai and Binet, that doctors use in order to:
◦Determine the extent of progression of the disease
◦Develop an optimal treatment plan
◦Predict the most likely outcome (prognosis) in terms of expected years of survival
Understanding the Standard Treatments...and the Treatment Options
Because currently there is no known cure for CLL, understanding the standard treatments - and the treatment options - is critical in attempting to prolong survival and maintain the patient's overall functional ability and quality of life. As you read through the section of the Guidebook that focuses on the treatments for CLL, you will specifically learn about:
•Which patients with CLL do not require any treatment for several years and may benefit from a "watchful waiting" approach where the disease progression is monitored carefully but no specific CLL treatment is given.
•The National Cancer Institutes guidelines for determining when initial treatment of CLL is indicated and should be started.
•The two most commonly used classes of chemotherapeutic agents that are used for the treatment of CLL, known as alkylating agents and purine nucleoside analogs.
•A new alkylating agent called bendamustine (Treanda) that was recently approved for the treatment of CLL.
•The side-effects associated with CLL chemotherapy and how to minimize their impact on your quality of life.
•A novel approach known as monoclonal antibody immunotherapy that has recently come into clinical practice which gives doctors the ability to preferentially target and destroy CLL cells. Examples of monoclonal antibodies that may be used for the treatment of CLL include:
◦Alemtuzumab (Campath)
◦Rituximab (Rituxan)
◦Ofatumumab (Arzerra) - a new monoclonal antibody that was approved for the treatment of CLL in October 2009.
•The role of stem cell transplantation in the management of patients with CLL, including the risks and benefits of this procedure.
•The complications, such as infection, anemia, and secondary cancers that may occur in people with CLL, including the management of these serious complications.
•The treatment options for patients with CLL who experience recurrent disease, meaning that the leukemia has come back after the patient had been in remission for a period of time.
•The role of complementary and alternative therapies in the management of patients with CLL.
•The prognosis (outlook) for people with CLL and the important factors that have a significant impact in predicting the overall chances of recovery and survival.
•Quality of life issues such as sleep disorders, fatigue, weight loss, and psychological stress that can negatively affect people with CLL and how to minimize the impact and cope better with these issues.
•Important questions to ask your doctor about CLL.
A "One-of-a-Kind" Reference Guidebook on Chronic Lymphocytic Leukemia that Goes Way Beyond the Fundamentals
Since 1996, when Medifocus was founded, we've learned that many people with Chronic Lymphocytic Leukemia are seeking more specific information that goes beyond the fundamentals, such as the causes, diagnosis, standard treatments, and treatment options. That's why we developed a "one-of-a-kind" reference Guidebook that goes way beyond the basics and also includes the following sections:
•A Guide to Recent Medical Literature on Chronic Lymphocytic Leukemia - This section of the Guidebook contains an extensive bibliography of over 100 references to recently published articles about Chronic Lymphocytic Leukemia in authoritative, peer-reviewed medical journals with links to the absracts (summaries) of the articles. These articles represent the latest advances in the field and focus on cutting-edge research, new developments, and the lessons learned from recently published clinical trials involving patients with Chronic Lymphocytic Leukemia. This is the same level of that is used by doctors who treat people with Chronic Lymphocytic Leukemia to keep abreast of the latest developments and breakthroughs in this specialized field of medicine.
•Centers of Research for Chronic Lymphocytic Leukemia - We've compiled a unique directory of doctors, hospitals, medical centers, and research institutions with special interest and, in many cases, clinical expertise in managing people with Chronic Lymphocytic Leukemia. The "Centers of Research" directory is a valuable resource for quickly identifying and locating leading medical authorities and medical institutions both within the United States and other countries who are considered to be at the forefront in clinical research and treatment of Chronic Lymphocytic Leukemia. You'd have to spend days - or even weeks - attempting to compile your own list of doctors and medical centers but, with the "Centers of Research" directory, the information is already right at your fingertips. All you have to do is act on the information by selecting and contacting the experts or medical institutions listed in the directory by state and country.
•Organizations and Support Groups for Chronic Lymphocytic Leukemia - The Guidebook also includes a directory of organizations and support groups whose goal is to help people with Chronic Lymphocytic Leukemia by providing access to information, resources, and services. Many of these organizations can answer your specific questions, enable you to "network" with other patients, and provide guidance in areas such as financial, social, or medical-legal issues. This valuable directory of organizations and support groups includes complete contact information, including phone numbers and E-mail addresses.
The Guidebook is a Value-Added Proposition that Comes with a Risk-Free Satisfaction Guarantee so that...You have Nothing to Lose and Everything to Gain
Still not sure if you'll benefit from the Medifocus Guidebook on Chronic Lymphocytic Leukemia? Still not convinced that the information included in the Guidebook is worth the minimal cost? If that's the case, then please consider the following value-added proposition that comes standard with your purchase of the Guidebook:
•Free Updates for One Year - With your initial purchase of the Guidebook, you also receive access to free updates for one-full year. The Guidebook is updated with new information every 4 to 6 months, so that you will be able to access the updated information several times during the course of a year for up to one full year after the date of your initial purchase.
•Free Digest E-Mail Alerts - When you purchase the Guidebook, you will also automatically receive a free subscription to our monthly newsletter - the Medifocus Digest Alert for Chronic Lymphocytic Leukemia. This is an expertly selected listing of the latest articles published in the medical literature about Chronic Lymphocytic Leukemia with convenient links to the abstracts of the articles that focus on cutting-edge research, clinical trials, and the latest treatment advances. The Medifocus Digest Alert for Chronic Lymphocytic Leukemia is automatically delivered straight to your "inbox" monthly and is a valuable resource for keeping up with the latest developments in Chronic Lymphocytic Leukemia almost as soon as the new information is published in the medical literature.
•10% Discount - For a limited time, you can purchase the Medifocus Guidebook on Chronic Lymphocytic Leukemia at a special 10% discount off the regular list price. Your 10% discount will automatically be applied when you go to "Checkout".
•Risk-Free Satisfaction Guarantee - Your purchase comes with our RISK-FREE satisfaction guarantee. If, for whatever reason, you are not totally satisfied with the content of your Guidebook, simply contact us within 30-days of your purchase for a prompt, full refund. We are so confident that you will be satisfied with your Guidebook that we offer this RISK-FREE satisfaction guarantee unconditionally - no questions and no hassles.
Order Your Copy of the Medifocus Guidebook on Chronic Lymphocytic Leukemia Today!
The Medifocus Guidebook on Chronic Lymphocytic Leukemia (135 pages; last updated August 24, 2010) is available in the following two convenient formats:
•PRINTED GUIDEBOOK - Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.):
◦Regular List Price = $32.95
◦Less 10% Discount = - $3.30
◦Your Discounted Price = $29.65 (excluding shipping & handling)
•ELECTRONIC GUIDEBOOK - Available for immediate download as a PDF document:
◦Regular List Price = $24.95
◦Less 10% Discount = - $2.50
◦Your Discounted Price = $22.45
To Place Your Order by Telephone, please call us:
•Within the United States (toll free): 1-800-965-3002
•Outside the United States: 1-301-649-9300
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia
at a Special 10% Discount
Updated: August 24, 2010
135 Pages
This one of a kind Guidebook offers:
•Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
•High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
•Timely, up to date content with free guidebook updates for 1 year.
•A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
•Over 130,000 Guidebooks Sold
•100% Risk Free Money Back Guarantee
--------------------------------------------------------------------------------
Purchase this Guidebook
The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:
PRINTED GUIDEBOOK - Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.):
•Regular List Price = $32.95
•Less 10% Discount = - $3.30
•Discounted Price = $29.65 (excluding shipping & handling)
ELECTRONIC GUIDEBOOK - Available for immediate download as a PDF document:
•Regular List Price = $24.95
•Less 10% Discount = - $2.50
•Discounted Price = $22.45
Order by Telephone
Call Toll Free in the U.S.
800-965-3002
From Outside the U.S.
301-649-9300
--------------------------------------------------------------------------------
What Our Customers Are Saying...
"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom
--------------------------------------------------------------------------------
Get the Medifocus Digest Alert on Chronic Lymphocytic Leukemia. Yours FREE! View Sample
Enter your email address:
I have read and agreed to the Medifocus Privacy Policy.
HomeWho We AreMedical Advisory BoardContactSupport
Privacy Policy © 1996-2010 Medifocus.com, Inc. or its affiliates Page Updated on: August 24, 2010
Medifocus Digest Alert
Each month hundreds of thousands of consumers and healthcare professionals search the National Library of Medicine's MEDLINE database seeking the latest information on their disease/condition. Conducting a thorough and effective MEDLINE search is both a time consuming and daunting task. At Medifocus, we have developed an effective solution to this problem that we call the Medifocus Digest Alert. Each month our staff of expert researchers searches MEDLINE for the latest advances in research and clinical medicine for over 30 diseases/conditions.
The Medifocus Digest Alert is an expertly selected listing of the latest medical journal articles published in MEDLINE for each disease/condition with direct links to the specific article summaries (abstracts) focusing on CUTTING EDGE RESEARCH, CLINICAL TRIALS, and the LATEST TREATMENT ADVANCES.
When you subscribe to the Medifocus Digest Alert, it is likely that you will have access to newly published information about your disease/condition even sooner than your doctor! And best of all...subscribing to the Medifocus Digest Alert is absolutely FREE.
STEP 1: SELECT YOUR DISEASES/CONDITIONS OF INTEREST STEP 2: ENTER YOUR EMAIL ADDRESS
Abdominal Aortic Aneurysm
Acoustic Neuroma
Alzheimer's Disease
Ankylosing Spondylitis
Atrial Fibrillation
Bipolar Disorder
Bladder Cancer
Carcinoid Tumor
Chronic Fatigue Syndrome
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Chronic Obstructive Pulmonary Disease
Chronic Pancreatitis
Cluster Headache
Congestive Heart Failure
Ductal Carcinoma in Situ of the Breast
Erectile Dysfunction
Female Infertility
Fibromyalgia
Gastroesophageal Reflux Disease
Glioblastoma
Graves' Disease
Hereditary Hemochromatosis
Lymphedema
Meniere's Disease
Migraine Headache
Multiple Myeloma
Myelodysplastic Syndromes
Non-Hodgkin's Lymphoma
Non-Small Cell Lung Cancer
Obsessive-Compulsive Disorder
Obstructive Sleep Apnea Syndrome
Osteoarthritis of the Knee
Osteoporosis
Parkinson's Disease
Peripheral Neuropathy
Polycystic Kidney Disease
Polycystic Ovary Syndrome
Reflex Sympathetic Dystrophy
Renal Cell Carcinoma
Restless Legs Syndrome
Rheumatoid Arthritis
Scleroderma
Sjogren's Syndrome
Small Cell Lung Cancer
Spondylolisthesis
Stroke Rehabilitation
Thoracic Outlet Syndrome
Tongue Cancer
Trigeminal Neuralgia
Vertigo
Email:
I have read and agreed to the Medifocus Privacy Policy.
HomeWho We AreMedical Advisory BoardContactSupportPrivacy Policy © 1996-2010 Medifocus.com, Inc. or its affiliates
posted by Unknown at
Tuesday, October 12, 2010
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home